Wellesley Pharmaceuticals, LLC
David Dill
CEO & PresidentWhale Bay & Co
- pharma & medtech companies for outlicensing/JV collaborations with our clients
- investors looking for early and late stage pharma, biotech and medtech investment opportunities
- (FoF)investors interested in investment in funds
Jasper Evers
Founding PartnerWPD Pharmaceuticals
WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.
Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust drug development pipeline with a focus on melanoma, brain cancer, leukemia, and pancreatic cancer. Notably, these funds do not include $14 million USD in grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland.
With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically positioned to enter the market with blockbuster potential.
Mariusz Olejniczak
CEOwww.eudendron.com
Mauro Angiolini
CEOXuanzhu Biopharmaceutical Co., Ltd.
Jasper Pei
BD managerZY Therapeutics Inc.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. The key platform patent was awarded by USPTO in 2019. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 18 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.
Jian Bao
CEO凯因科技
Kawin Technology is a Chinese biopharma engaging in liver disease and virus-related disease.
The turnover in 2019 is over 800 million RMB (115 millon USD).
We are now in IPO process and projected to be listed in China this year.
What we are looking for:
Antivirals and liver disease: early staged in-licensing
Technical collaboration, out-licensing
Yu Cai
BD Head成都百裕制药股份有限公司
Baiyu , founded in 2005, is a pharmaceutical enterprise engaged in developing, manufacturing and distributing of high-quality pharmaceutical products and APIs. With about 1000 employees, Baiyu now has 6 subsidiaries including Golden Ginkgo Pharmaceutical Co., Ltd., Ginkgolide Pharmaceuticals Co., Ltd., Sunshine Ginkgo Agriculture Co.Ltd., Sichuan Yu Jian Pharmaceutical Co., Ltd. and Ginkgo Yukang Informatics Co.,Ltd., Ginkgo Yuda Pharmaceutical Co.,Ltd., et al.
Currently,we have 8 finished pharmaceutical products and 2 APIs on the market. Based on Quality-by-Design concept, our manufacturing sites strictly comply with cGMP and EU GMP. Ginkgolide injection, Enoxaparin sodium injection, Lansoprazole for injection are our main products.
Baiyu is growing fastly and has been awarded“National High-tech Enterprise”,“Sichuan Famous Brand”and“Enterprises with the most investment value in Chinese pharmaceutical industry”in 3 consecutive years.
The culture of kindness, Taiji and phoenix leads the way we behave and our vision is to constantly benefiting mankind to enjoy life-long well-being.